| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myeloproliferative Disorders | 6 | 2021 | 767 | 1.630 |
Why?
|
| Isochromosomes | 2 | 2021 | 55 | 1.200 |
Why?
|
| Emulsions | 2 | 2016 | 82 | 1.090 |
Why?
|
| Myelodysplastic Syndromes | 5 | 2021 | 2979 | 0.950 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 2 | 2021 | 118 | 0.890 |
Why?
|
| Polymerase Chain Reaction | 5 | 2016 | 3203 | 0.810 |
Why?
|
| Pathologists | 1 | 2021 | 91 | 0.750 |
Why?
|
| Biological Products | 1 | 2021 | 274 | 0.640 |
Why?
|
| Blood Platelet Disorders | 1 | 2017 | 37 | 0.600 |
Why?
|
| Loss of Heterozygosity | 1 | 2018 | 602 | 0.580 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2017 | 217 | 0.540 |
Why?
|
| Lymphoma, B-Cell | 4 | 2014 | 895 | 0.490 |
Why?
|
| Bone Marrow | 3 | 2021 | 2358 | 0.480 |
Why?
|
| DNA Mutational Analysis | 5 | 2017 | 2283 | 0.460 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2013 | 64 | 0.440 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 2012 | 16 | 0.440 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2014 | 2291 | 0.430 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2012 | 60 | 0.420 |
Why?
|
| Genes, bcl-2 | 1 | 2012 | 166 | 0.420 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1046 | 0.410 |
Why?
|
| Aurora Kinase A | 1 | 2013 | 202 | 0.410 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 1516 | 0.410 |
Why?
|
| Genes, myc | 1 | 2012 | 358 | 0.380 |
Why?
|
| Neoplasms, Second Primary | 3 | 2015 | 1350 | 0.380 |
Why?
|
| Karyotyping | 5 | 2017 | 1022 | 0.370 |
Why?
|
| Hematologic Neoplasms | 2 | 2021 | 1870 | 0.360 |
Why?
|
| Lymphoma, T-Cell | 1 | 2013 | 361 | 0.350 |
Why?
|
| Chromosome Deletion | 2 | 2013 | 1005 | 0.340 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2021 | 3552 | 0.340 |
Why?
|
| Immunophenotyping | 6 | 2017 | 1681 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2011 | 641 | 0.330 |
Why?
|
| Leukemia, Myeloid, Acute | 5 | 2016 | 6915 | 0.300 |
Why?
|
| Genes, p53 | 1 | 2011 | 1090 | 0.300 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2012 | 755 | 0.300 |
Why?
|
| Flavoproteins | 1 | 2006 | 33 | 0.280 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2012 | 2359 | 0.270 |
Why?
|
| Fusion Proteins, bcr-abl | 3 | 2016 | 1094 | 0.270 |
Why?
|
| DNA | 1 | 2013 | 2693 | 0.260 |
Why?
|
| Leukemia, B-Cell | 2 | 2014 | 117 | 0.230 |
Why?
|
| Circadian Rhythm | 1 | 2006 | 330 | 0.230 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2006 | 622 | 0.210 |
Why?
|
| Transcriptional Activation | 1 | 2006 | 1070 | 0.200 |
Why?
|
| Mutation | 7 | 2021 | 15179 | 0.200 |
Why?
|
| Humans | 31 | 2021 | 261506 | 0.190 |
Why?
|
| Immunohistochemistry | 5 | 2013 | 7548 | 0.180 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 2 | 2014 | 387 | 0.180 |
Why?
|
| Trans-Activators | 1 | 2006 | 1555 | 0.170 |
Why?
|
| Breast Implants | 2 | 2014 | 391 | 0.170 |
Why?
|
| Germ Cells | 1 | 2021 | 335 | 0.170 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2013 | 1217 | 0.170 |
Why?
|
| Antigens, CD | 2 | 2014 | 1385 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 3639 | 0.160 |
Why?
|
| Models, Molecular | 1 | 2021 | 1732 | 0.140 |
Why?
|
| Microfluidics | 1 | 2016 | 33 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2013 | 810 | 0.130 |
Why?
|
| Clonal Evolution | 1 | 2017 | 253 | 0.130 |
Why?
|
| Calreticulin | 1 | 2015 | 74 | 0.130 |
Why?
|
| Cytogenetic Analysis | 2 | 2014 | 568 | 0.120 |
Why?
|
| Disease Susceptibility | 1 | 2017 | 538 | 0.120 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 4053 | 0.120 |
Why?
|
| RNA, Messenger | 2 | 2016 | 6150 | 0.120 |
Why?
|
| CD5 Antigens | 1 | 2014 | 112 | 0.120 |
Why?
|
| Prognosis | 5 | 2021 | 21713 | 0.120 |
Why?
|
| Poly(A)-Binding Proteins | 1 | 2013 | 32 | 0.110 |
Why?
|
| Pedigree | 1 | 2017 | 1890 | 0.110 |
Why?
|
| Family | 1 | 2017 | 736 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2015 | 2232 | 0.110 |
Why?
|
| RNA, Neoplasm | 1 | 2016 | 771 | 0.110 |
Why?
|
| Adult | 10 | 2021 | 77950 | 0.110 |
Why?
|
| Neoplasms | 3 | 2014 | 15193 | 0.110 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2014 | 114 | 0.110 |
Why?
|
| Composite Lymphoma | 1 | 2012 | 15 | 0.110 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2016 | 560 | 0.110 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 2 | 2014 | 301 | 0.110 |
Why?
|
| Benzene | 1 | 2012 | 45 | 0.110 |
Why?
|
| Leukemia, Prolymphocytic, B-Cell | 1 | 2012 | 7 | 0.110 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2016 | 430 | 0.110 |
Why?
|
| Xenobiotics | 1 | 2012 | 44 | 0.110 |
Why?
|
| Iatrogenic Disease | 1 | 2013 | 183 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2021 | 4757 | 0.110 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2012 | 63 | 0.110 |
Why?
|
| Gene Rearrangement | 2 | 2013 | 783 | 0.100 |
Why?
|
| K562 Cells | 1 | 2012 | 338 | 0.100 |
Why?
|
| Aged | 10 | 2015 | 70117 | 0.100 |
Why?
|
| Splenic Neoplasms | 1 | 2012 | 119 | 0.100 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2013 | 181 | 0.100 |
Why?
|
| Neoplasm Grading | 2 | 2013 | 1742 | 0.100 |
Why?
|
| Female | 14 | 2017 | 141928 | 0.100 |
Why?
|
| Thiazoles | 1 | 2015 | 726 | 0.100 |
Why?
|
| Male | 11 | 2017 | 123000 | 0.090 |
Why?
|
| Lymphoma, Mantle-Cell | 2 | 2014 | 713 | 0.090 |
Why?
|
| Middle Aged | 10 | 2016 | 86204 | 0.090 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2013 | 690 | 0.090 |
Why?
|
| Oncogenes | 1 | 2013 | 673 | 0.090 |
Why?
|
| Autoimmune Diseases | 1 | 2013 | 402 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2021 | 5539 | 0.090 |
Why?
|
| Biopsy | 1 | 2017 | 3443 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 14889 | 0.090 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 698 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 1033 | 0.080 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 2796 | 0.080 |
Why?
|
| Aged, 80 and over | 5 | 2014 | 29902 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 2508 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1493 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 1375 | 0.070 |
Why?
|
| Blotting, Western | 1 | 2013 | 3536 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2014 | 6100 | 0.070 |
Why?
|
| Cryptochromes | 1 | 2006 | 14 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 1162 | 0.070 |
Why?
|
| Period Circadian Proteins | 1 | 2006 | 52 | 0.070 |
Why?
|
| CLOCK Proteins | 1 | 2006 | 35 | 0.070 |
Why?
|
| ARNTL Transcription Factors | 1 | 2006 | 57 | 0.070 |
Why?
|
| Disease Progression | 1 | 2017 | 6682 | 0.070 |
Why?
|
| Crosses, Genetic | 1 | 2006 | 241 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2006 | 96 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2013 | 1586 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2021 | 37905 | 0.060 |
Why?
|
| Diagnosis, Differential | 4 | 2016 | 4744 | 0.060 |
Why?
|
| Hodgkin Disease | 1 | 2013 | 1429 | 0.060 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 2527 | 0.060 |
Why?
|
| Genes, Reporter | 1 | 2006 | 798 | 0.060 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2014 | 2390 | 0.060 |
Why?
|
| Multiprotein Complexes | 1 | 2006 | 395 | 0.060 |
Why?
|
| Flow Cytometry | 3 | 2014 | 3033 | 0.060 |
Why?
|
| Biomarkers, Tumor | 4 | 2014 | 10331 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 6550 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2015 | 3518 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6207 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2006 | 492 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2006 | 1113 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 3230 | 0.050 |
Why?
|
| Sensitivity and Specificity | 3 | 2014 | 4971 | 0.050 |
Why?
|
| Disease-Free Survival | 3 | 2021 | 10001 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 1555 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2013 | 9244 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 15694 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 3101 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 14551 | 0.040 |
Why?
|
| Philadelphia Chromosome | 1 | 2021 | 793 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2006 | 2045 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 4654 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2006 | 5710 | 0.030 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2016 | 106 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 6942 | 0.030 |
Why?
|
| Semiconductors | 1 | 2014 | 22 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 15862 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 3343 | 0.030 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2014 | 37 | 0.030 |
Why?
|
| Leukocytosis | 1 | 2014 | 112 | 0.030 |
Why?
|
| Lewis X Antigen | 1 | 2013 | 46 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2016 | 829 | 0.030 |
Why?
|
| Reed-Sternberg Cells | 1 | 2013 | 44 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 208 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 5159 | 0.030 |
Why?
|
| Young Adult | 1 | 2012 | 21445 | 0.030 |
Why?
|
| T-Cell Intracellular Antigen-1 | 1 | 2013 | 16 | 0.030 |
Why?
|
| Fucosyltransferases | 1 | 2013 | 76 | 0.030 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2014 | 115 | 0.030 |
Why?
|
| Histiocytes | 1 | 2013 | 94 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 6009 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 2013 | 206 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2014 | 299 | 0.030 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2012 | 47 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2013 | 205 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2014 | 324 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 2013 | 218 | 0.030 |
Why?
|
| Adolescent | 1 | 2012 | 31252 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2012 | 247 | 0.030 |
Why?
|
| Dasatinib | 1 | 2015 | 862 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2013 | 289 | 0.030 |
Why?
|
| Splenectomy | 1 | 2012 | 158 | 0.020 |
Why?
|
| Device Removal | 1 | 2013 | 337 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2013 | 1037 | 0.020 |
Why?
|
| Child | 1 | 2012 | 29154 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2012 | 234 | 0.020 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2014 | 273 | 0.020 |
Why?
|
| Nose Neoplasms | 1 | 2013 | 229 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2013 | 671 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2013 | 875 | 0.020 |
Why?
|
| Time Factors | 2 | 2013 | 12926 | 0.020 |
Why?
|
| Lymphoma, Follicular | 1 | 2014 | 587 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2014 | 731 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2013 | 673 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2013 | 966 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 943 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2013 | 1245 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 1656 | 0.020 |
Why?
|
| Recurrence | 1 | 2016 | 4758 | 0.020 |
Why?
|
| Remission Induction | 1 | 2013 | 3569 | 0.020 |
Why?
|
| Breast | 1 | 2013 | 1344 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 4109 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 2483 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 4988 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2013 | 2086 | 0.020 |
Why?
|
| Mice | 1 | 2006 | 34495 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 4892 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 3719 | 0.010 |
Why?
|
| Tumor Microenvironment | 1 | 2013 | 2864 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2014 | 32848 | 0.010 |
Why?
|
| Survival Rate | 1 | 2016 | 12221 | 0.010 |
Why?
|
| Phenotype | 1 | 2013 | 6295 | 0.010 |
Why?
|
| Animals | 1 | 2006 | 59536 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2013 | 7226 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 8865 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 13658 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 14289 | 0.010 |
Why?
|